PHENERGAN (promethazine hydrochloride) by Thayer Medical is clinical pharmacology promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1956.
Drug data last refreshed 31m ago · AI intelligence enriched 4w ago
PHENERGAN (promethazine hydrochloride) is a phenothiazine-derived H1 receptor antagonist approved in 1956 for injectable use. It provides antihistaminic, sedative, and antiemetic effects with onset within 20 minutes and duration of 4-12 hours. The drug is metabolized hepatically and lacks significant dopamine antagonism compared to antipsychotic phenothiazines.
As a legacy injectable nearing loss of exclusivity with modest competitive pressure (30), brand teams face headwinds in market defense and likely operate with lean staffing.
CLINICAL PHARMACOLOGY Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on PHENERGAN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Thayer Medical is hiring 1 role related to this product
Working on PHENERGAN means joining a legacy product team managing a mature, genericized injectable in a stable but non-growth environment. Career advancement opportunities are limited compared to growth-stage products, though roles offer deep expertise in hospital/institutional channel management and generic competition defense.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo